WO2026008665 - BINDERS OF THE PD-1•PD-L1 COMPLEX AND THEIR USE
National phase entry is expected:
Publication Number
WO/2026/008665
Publication Date
08.01.2026
International Application No.
PCT/EP2025/068744
International Filing Date
01.07.2025
Title **
[English]
BINDERS OF THE PD-1•PD-L1 COMPLEX AND THEIR USE
[French]
LIANTS DU COMPLEXE PD-1•PD-L1 ET LEUR UTILISATION
Applicants **
VIB VZW
VRIJE UNIVERSITEIT BRUSSEL
Inventors
STEYAERT, Jan
WOHLKÖNIG, Alexandre
ZÖGG, Thomas
MIGLIANICO, Marie
LAEREMANS, Toon
TRIEST, Sarah
CAMBRÉ, Isabelle
STORTELERS, Catelijne
PARDON, Els
Priority Data
24185761.4
01.07.2024
EP
25185826.2
27.06.2025
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3726 | |
| EPO | Filing, Examination, Granting | 19861 | |
| Japan | Filing, Examination, Granting | 2556 | |
| South Korea | Filing, Examination, Granting | 2922 | |
| USA | Filing, Examination, Granting | 10090 |
Total:
39,155
Contact Us
Abstract[English]
This disclosure relates to an immunoglobulin single variable domain (ISVD)-containing modulator that allosterically binds to a three-dimensional (3D) epitope present on the human PD-1•PDL1 (hPD-1•hPD-L1) complex. The modulator regulates cooperativity within this complex, thereby affecting the binding affinity between hPD-1 and hPD-L1 and/or downstream signaling pathways. Specifically, the allosteric modulator of this invention selectively induces positive cooperativity in the hPD-1•hPD-L1 complex, thus suppressing immune responses in a spatiotemporally restricted manner. Accordingly, such allosteric modulators are useful as therapeutic agents for inflammatory diseases, such as autoimmune diseases, allergic diseases, or graft-versus-host disease (GVHD).[French]
La présente divulgation concerne un modulateur contenant un domaine variable unique d'immunoglobuline (ISVD) qui se lie de manière allostérique à un épitope tridimensionnel (3D) présent sur le complexe PD-1•PDL1 (hPD-1•hPD-L1) humain. Le modulateur régule la coopérativité dans ce complexe, affectant ainsi l'affinité de liaison entre hPD-1 et hPD-L1 et/ou des voies de signalisation en aval. Plus particulièrement, le modulateur allostérique selon la présente invention induit sélectivement une coopérativité positive dans le complexe hPD-1•hPD-L1, ce qui permet de supprimer les réponses immunitaires de manière à limitation spatiotemporelle. En conséquence, de tels modulateurs allostériques sont utiles en tant qu'agents thérapeutiques pour des maladies inflammatoires, telles que des maladies auto-immunes, des maladies allergiques ou une maladie du greffon contre l'hôte (GVHD).